RxDoctor Payments Data

Shulamit Manahimov, NP

Adult Health · Rego Park, NYNPI 1497376974

Payments from drug & device makers

$6,632in general payments, 2019–2025

Across 294 payments — averaging $22.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Pfizer$844
  • Lundbeck LLC$313
  • Axsome Therapeutics, Inc.$266
  • Scilex Pharmaceuticals Inc.$226
  • Biohaven Pharmaceutical Holding Company Ltd.$205
  • plus $2K from 23 others

What the payments were for

  • Food & beverage$6,632100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,632 in reported general payments places this provider in the 95th percentile of 3,828 adult health providers in New York.

See all adult health providers in New York

Medicare billing

Part B allowed, 2024
$30,414
Medicare patients
121
Services billed
1,352

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate102$185,277
UbrelvyUbrogepant47$75,253
QuliptaAtogepant32$37,042
Emgality PenGalcanezumab-Gnlm27$20,074
Doxepin Hcl99$19,102
Ajovy AutoinjectorFremanezumab-Vfrm24$17,996
NamzaricMemantine Hcl/Donepezil Hcl25$17,075
Diclofenac Potassium13$12,235
Diclofenac Sodium26$9,372
AdlarityDonepezil Hcl15$6,403
ZtlidoLidocaine11$3,984
Donepezil Hcl247$2,694
Risperidone OdtRisperidone20$2,030
Lacosamide27$1,869
Memantine Hcl154$1,365

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt$844$185,277102 claims
AbbVieUbrelvy, Qulipta, Namzaric$3,238$129,370104 claims
Corium, LLCAdlarity$69$6,40315 claims
Scilex Pharmaceuticals Inc.Ztlido$226$3,98411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,828 adult health providers in New York.

Other adult health in Rego Park

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →